---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-094724"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:14:55.951290+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix updates AXPAXLI trials: SOL-1 topline Q1 2026, SOL-R H1 2027; initiates NPDR Phase 3

## Summary
- SOL-1 Phase 3 wet AMD trial topline results expected Q1 2026; retention >95%, rescue events >95% meet criteria, no new safety signals.
- SOL-R Phase 3 wet AMD trial enrollment completed, randomization ongoing; topline results expected H1 2027.
- Plans to initiate SOL-X long-term extension trial following SOL-1/SOL-R; subjects receive AXPAXLI every 24 weeks for 3 years.
- Initiates Phase 3 NPDR program with HELIOS-2 (432 subjects) and HELIOS-3 (930 subjects); FDA SPA agreement for HELIOS-2 design.
- Received notice of allowance from USPTO for patent covering treating ocular diseases with AXPAXLI; expiration expected 2044.

## SEC filing metadata
- accession: 0001104659-25-094724
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/0001104659-25-094724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/tm2527344d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-094724
- JSON: https://secwatch.observer/filing/0001104659-25-094724.json
- Plain text: https://secwatch.observer/filing/0001104659-25-094724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.